Search research articles
Contact Us
Filters
Showing results (41-50 of 59) with videos related to
Page
of 6
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)
|
May 19, 2019
Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients
Matthias A Cassia, Federico Alberici, Rachel B Jones, et al.
Annals of the Rheumatic Diseases
|
March 6, 2015
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial
Rachel B Jones, Shunsuke Furuta, Jan Willem Cohen Tervaert, et al.
Trials
|
March 11, 2023
A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol
Mark E McClure, Seerapani Gopaluni, James Wason, et al.
The New England Journal of Medicine
|
July 22, 2010
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis
Rachel B Jones, Jan Willem Cohen Tervaert, Thomas Hauser, et al.
BMC Nephrology
|
June 1, 2022
SARS-COV-2 vaccine responses in renal patient populations
Rona M Smith, Daniel J Cooper, Rainer Doffinger, et al.
Rheumatology (Oxford, England)
|
September 22, 2018
A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis
Ruth J Pepper, Stephen P McAdoo, Sarah M Moran, et al.
Lancet (London, England)
|
January 23, 2022
Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients
Edward J Carr, Mary Wu, Ruth Harvey, et al.
Rheumatology (Oxford, England)
|
January 29, 2019
A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis
Ruth J Pepper, Stephen P McAdoo, Sarah M Moran, et al.
BMC Nephrology
|
March 28, 2026
The UK Eastern Network for Kidney Inflammatory Disease (ENKID) MDT at 24 months: advancing access to high-cost drugs, clinical trials, and complex case management in renal autoimmune diseases
Lucy Francis, Olivia Kanka, Ondrej Suchanek, et al.
Rheumatology (Oxford, England)
|
May 25, 2026
Incorporating frailty and disease severity into treatment decisions for older patients with ANCA-associated vasculitis
Mark E McClure, Ayonija Sundararajan, Karl Emil Nelveg-Kristensen, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 59) with videos related to
Sort By:
Page
of 6
Arthritis & Rheumatology (Hoboken, N.J.)
|
May 19, 2019
Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients
Matthias A Cassia, Federico Alberici, Rachel B Jones, et al.
Annals of the Rheumatic Diseases
|
March 6, 2015
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial
Rachel B Jones, Shunsuke Furuta, Jan Willem Cohen Tervaert, et al.
Trials
|
March 11, 2023
A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol
Mark E McClure, Seerapani Gopaluni, James Wason, et al.
The New England Journal of Medicine
|
July 22, 2010
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis
Rachel B Jones, Jan Willem Cohen Tervaert, Thomas Hauser, et al.
BMC Nephrology
|
June 1, 2022
SARS-COV-2 vaccine responses in renal patient populations
Rona M Smith, Daniel J Cooper, Rainer Doffinger, et al.
Rheumatology (Oxford, England)
|
September 22, 2018
A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis
Ruth J Pepper, Stephen P McAdoo, Sarah M Moran, et al.
Lancet (London, England)
|
January 23, 2022
Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients
Edward J Carr, Mary Wu, Ruth Harvey, et al.
Rheumatology (Oxford, England)
|
January 29, 2019
A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis
Ruth J Pepper, Stephen P McAdoo, Sarah M Moran, et al.
BMC Nephrology
|
March 28, 2026
The UK Eastern Network for Kidney Inflammatory Disease (ENKID) MDT at 24 months: advancing access to high-cost drugs, clinical trials, and complex case management in renal autoimmune diseases
Lucy Francis, Olivia Kanka, Ondrej Suchanek, et al.
Rheumatology (Oxford, England)
|
May 25, 2026
Incorporating frailty and disease severity into treatment decisions for older patients with ANCA-associated vasculitis
Mark E McClure, Ayonija Sundararajan, Karl Emil Nelveg-Kristensen, et al.
Page
of 6